Regulatory FDA approves AstraZeneca’s Saphnelo for SLE Pharmaceutical TechnologyAstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.Immunology & InflammationRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE. Immunology & Inflammation Read full story Post navigation Previous: Oruka surges as long-acting psoriasis drug shows early promiseNext: BioMarin acquires Amicus Therapeutics for $4.8bn Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026